MLTX — MoonLake Immunotherapeutics
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1821586 ·
Last close
$18.23
Market Cap
$1.34B
52W High
$21.00
52W Low
$15.76
ADV30
886,104
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -70,024,000 | -69,707,000 | 400,374,000 | 298,490,000 | 146,350,000 |
| Dec 2025 | 0 | — | -65,218,000 | -62,427,000 | 424,433,000 | 334,517,000 | 119,952,000 |
| Sep 2025 | 0 | — | -71,434,000 | -69,729,000 | 414,335,000 | 350,736,000 | 123,144,000 |
| Jun 2025 | 0 | — | -60,698,000 | -55,220,000 | 460,096,000 | 306,681,000 | 102,152,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-196,007,000
Investing CF
$202,992,000
Financing CF
$145,997,000
CapEx
$-342,567
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.32
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-462,911,000
Inventory
—
Receivables
$4,869,000
ST Investments
$59,451,000
EBIT TTM
$-222,464,000
Pretax Income TTM
$-229,711,000
Interest Exp TTM
$7,247,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -244,834,000 | -227,318,000 | 424,433,000 | 119,952,000 | — | -196,007,000 |
| Dec 2024 | 0 | -143,091,000 | -118,936,000 | 477,933,000 | 24,542,000 | — | -116,587,000 |
| Dec 2023 | 0 | -54,123,000 | -36,007,000 | 526,540,115 | 13,049,096 | — | -42,778,000 |
| Dec 2022 | 0 | -65,061,417 | -49,973,249 | 76,843,301 | 8,076,603 | — | -55,893,900 |
TTM Snapshot
Revenues TTM
$-141,718,488
NetIncome TTM
$-55,278,174
OpCashFlow TTM
$0
Assets (Latest)
$477,933,000
Forward EPS
$-3.45
Max Pain — expiry 2026-08-21
max pain strike: $15.00 · spot: $18.23 · call oi: 8,436 · put oi: 2,204
Expected Move to 2026-08-21:
±$7.18
(39.36%) —
implied range
$11.05 –
$25.40
· ATM straddle on $18.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SEPN | Septerna, Inc. | $1.38B | $30.65 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.30B | $27.94 | — |
| HROW | HARROW, INC. | $1.27B | $34.17 | — |
| KALV | KalVista Pharmaceuticals, Inc. | $1.43B | $26.81 | — |
| MPLT | MapLight Therapeutics, Inc. | $1.26B | $29.46 | — |
News headlines (Yahoo Finance, 1h cache)
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway
2026-05-12 16:17 · Yahoo
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
2026-05-11 20:15 · Yahoo
MoonLake (MLTX) Shares Gain After Positive FDA Meeting on Sonelokimab Filing
2026-05-11 14:16 · Yahoo
Update: MoonLake Immunotherapeutics Q1 Net Loss Widens
2026-05-11 09:05 · Yahoo
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
2026-05-10 13:00 · Yahoo
Avalo shares spike on skin drug data; BioNTech to cut staff
2026-05-06 10:30 · Yahoo
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
2026-04-18 14:37 · Yahoo
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
2026-04-07 18:27 · Yahoo
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa
2026-04-05 07:10 · Yahoo
MoonLake’s lead asset shows durability in late-stage HS studies
2026-03-31 16:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.